TR200102334T2 - Matris metaloproteinazların önleyicileri olarak pirimidin-2,4,6-trionlar. - Google Patents

Matris metaloproteinazların önleyicileri olarak pirimidin-2,4,6-trionlar.

Info

Publication number
TR200102334T2
TR200102334T2 TR2001/02334T TR200102334T TR200102334T2 TR 200102334 T2 TR200102334 T2 TR 200102334T2 TR 2001/02334 T TR2001/02334 T TR 2001/02334T TR 200102334 T TR200102334 T TR 200102334T TR 200102334 T2 TR200102334 T2 TR 200102334T2
Authority
TR
Turkey
Prior art keywords
cancer
substituted
gelatinase
aryloxy
formula
Prior art date
Application number
TR2001/02334T
Other languages
English (en)
Inventor
Helen Foley Louise
Edward Palermo Robert
Wang Ping
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of TR200102334T2 publication Critical patent/TR200102334T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

R1'in hidrojen, alkil, ikame edilmis alkil, alkenil, ikame edilmis alkenil, alkinil, ikame edilmis alkinil, alkoksi, ikame edilmis alkoksi, ariloksi veya alkilalkoksi, ve R2'nin ariloksi oldugu formül (I)'e ait yeni bilesikler; formül (I)'e ait asidik bir bilesigin farmasötik açidan kabul gören tuzlari ve bunlarin ön ilaçlari, jelatinaz-A'nin ve/veya jelatinaz-B'nin asiri tanimlanmasina bagli kanserin, özellikle de deri kanser, gögüs kanseri, prostat kanseri, kolon kanseri, akçiger kanseri, ve gastrik kanserin tedavisinde veya kontrolünde kullanilabilir ve bunlar, romatizmal arterit, osteoarterit, muhtelif skleroz, korneal ülserasyon, periodontal hastalik ve benzeri gibi hücre disi matrisin düzensiz ayrismasina bagli diger hastaliklar için de faydalidir.
TR2001/02334T 1999-02-12 2000-02-09 Matris metaloproteinazların önleyicileri olarak pirimidin-2,4,6-trionlar. TR200102334T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11990399P 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
TR200102334T2 true TR200102334T2 (tr) 2002-01-21

Family

ID=22387100

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02334T TR200102334T2 (tr) 1999-02-12 2000-02-09 Matris metaloproteinazların önleyicileri olarak pirimidin-2,4,6-trionlar.

Country Status (16)

Country Link
US (1) US6265578B1 (tr)
EP (1) EP1153015B1 (tr)
JP (1) JP3655551B2 (tr)
KR (1) KR100477160B1 (tr)
CN (1) CN1147481C (tr)
AR (1) AR035008A1 (tr)
AT (1) ATE277912T1 (tr)
AU (1) AU774487B2 (tr)
BR (1) BR0008109A (tr)
CA (1) CA2361605C (tr)
DE (1) DE60014323T2 (tr)
ES (1) ES2226790T3 (tr)
PT (1) PT1153015E (tr)
TR (1) TR200102334T2 (tr)
WO (1) WO2000047565A1 (tr)
ZA (1) ZA200106214B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301577A3 (en) * 2000-10-26 2006-02-28 Pfizer Prod Inc Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
KR20030061825A (ko) 2000-10-26 2003-07-22 화이자 프로덕츠 인크. 피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제
US6841671B2 (en) 2000-10-26 2005-01-11 Pfizer Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2003053940A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
ATE308544T1 (de) 2002-04-26 2005-11-15 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
AU2003223012A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
NI200300045A (es) * 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
EP1501834B1 (en) 2002-04-26 2005-09-07 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
TWI280128B (en) * 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
CN100548638C (zh) * 2003-08-22 2009-10-14 辛古勒斯技术股份公司 碟形基片的粘接方法及实现这种方法的设备
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
AU746853B2 (en) 1997-06-21 2002-05-02 Roche Diagnostics Gmbh Barbituric acid derivatives with antimetastatic and antitumor activity
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
ES2226790T3 (es) 2005-04-01
BR0008109A (pt) 2001-11-06
EP1153015B1 (en) 2004-09-29
AU774487B2 (en) 2004-07-01
EP1153015A1 (en) 2001-11-14
CA2361605A1 (en) 2000-08-17
AU2908500A (en) 2000-08-29
ATE277912T1 (de) 2004-10-15
WO2000047565A1 (en) 2000-08-17
PT1153015E (pt) 2004-12-31
KR100477160B1 (ko) 2005-03-17
US6265578B1 (en) 2001-07-24
JP3655551B2 (ja) 2005-06-02
CN1147481C (zh) 2004-04-28
CA2361605C (en) 2009-01-27
JP2002536439A (ja) 2002-10-29
DE60014323D1 (de) 2004-11-04
DE60014323T2 (de) 2006-02-16
ZA200106214B (en) 2002-10-28
KR20020011963A (ko) 2002-02-09
AR035008A1 (es) 2004-04-14
CN1339028A (zh) 2002-03-06

Similar Documents

Publication Publication Date Title
SE0202462D0 (sv) Novel use
TNSN04165A1 (en) Substituted hydroxyethylamines
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
MY138352A (en) Benzothiazole derivatives
TNSN06052A1 (en) 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
GB0128108D0 (en) Therapeutic use
SE0104334D0 (sv) Therapeutic agents
TR200102334T2 (tr) Matris metaloproteinazların önleyicileri olarak pirimidin-2,4,6-trionlar.
IL166412A0 (en) Novel use of benzothiazole derivatives
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
TR200101120T2 (tr) Serin proteaz inhibitörü
ATE437872T1 (de) Proteinkinaseinhibitoren
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
HUP0402422A2 (hu) Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE442375T1 (de) Cytarabin-monophosphate prodrugs
SE0301232D0 (sv) Novel use
MY129310A (en) C-4 carbonate taxanes
BR0114873A (pt) Imidazopiridinas polissubstituìdas
DE60325377D1 (de) Motilidverbindungen
ATE360428T1 (de) Analgetisches arzneimittel
RS20050294A (en) Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
BRPI0416678A (pt) pirazolpirimidinas
TR199900153T2 (tr) Hücre çogalmasini önlemek için ikame edilmis bisindolilmaleimitler.
PT1280527E (pt) Utilizacao de derivados de acriloil distamicina no tratamento de tumores associados a niveis de glutationa elevados